| BRIEF REPORT |
|
| Year : 2019 | Volume
: 37
| Issue : 4 | Page : 205-208 |
|
|
Efficacy of tofacitinib in patients with moderate-to-severe psoriasis who had inadequate responses to prior biologics
Yi-Wei Huang1, Tsen-Fang Tsai2
1 Department of Education, National Taiwan University Hospital, Taipei, Taiwan
2 Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan
Correspondence Address:
Dr. Tsen-Fang Tsai
Department of Dermatology, National Taiwan University Hospital, No. 7 Chung San South Road, Taipei
Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ds.ds_22_19
|
|
|
This retrospective observational study examined the effect of tofacitinib in two Phase 3 controlled studies. Patients (n = 15) were randomized to receive either tofacitinib 5 or 10 mg or placebo, twice daily. Most patients in both groups were responsive to tofacitinib at week 16. Four patients (25%) used two or more biological agents before tofacitinib. Two of these refractory patients demonstrated a response. In conclusion, tofacitinib provides a comparable therapeutic effect in both prior biologics responders and nonresponders during the initial 16 weeks, especially those exposed to etanercept. Tofacitinib remains a treatment choice in refractory patients who failed multiple previous biologics.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
